Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine

Author:

Chen Jing1234ORCID,Wang Xue5ORCID,Yuan Yuan2ORCID,Chen Haoting2ORCID,Zhang Lingpu6ORCID,Xiao Haihua6ORCID,Chen Jingqi2ORCID,Zhao Yongxiang7ORCID,Chang Jin4ORCID,Guo Weisheng2ORCID,Liang Xing-Jie12ORCID

Affiliation:

1. Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences (CAS) Center for Excellence in Nanoscience and CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, P. R. China.

2. Translational Medicine Center, Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, P. R. China.

3. School of Pharmacy, Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Binzhou Medical University, Yantai 264003, P. R. China.

4. School of Life Sciences, Tianjin University and Tianjin Engineering Center of Micro Nano Biomaterials and Detection Treatment Technology Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, P. R. China.

5. Department of Obstetrics and Gynecology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P. R. China.

6. Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.

7. National Center for International Research of Biotargeting Theranostics, Guangxi Key Laboratory of Biotargeting Theranostics, Collaborative Innovation Center for Targeting Tumour Theranostics and Therapy, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.

Abstract

Nanochemotherapy combats cisplatin resistance by exploiting increased intracellular hypoxia in cancer cells.

Funder

National Key Research and Development Program of China Stem Cell and Translational Research

The National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province of China

NSFC-German Research Foundation (DFG) project

Shandong Province Higher Educational Youth Innovation Talents Introduction and Cultivation Program-Chemical Biology Research Innovation Team

The Beijing-Tianjin-Hebei Basic Research Cooperation Project

NSFC international collaboration key project

Scientific Foundation of Binzhou Medical University

National Natural Science Foundation of China (NSFC) key projects

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3